


Hong Kong COVID-19 Snapshot

| | Hong Kong | | United States | |
|---|-----------|----------------|---------------|----------------|
| | # | Δ ¹ | # | Δ ¹ |
| Confirmed Cases | 13,048 | 6% | 67.6m | +43% |
| Deaths | 213 | - | 874,321 | +13% |
| Deaths per 1M | 28 | - | 2,618 | +13% |
| Testing rate per 1M | 4,128,836 | - | 2,582,225 | - |
| Population with at least one vaccination | ~68% | | ~75% | |

Hong Kong: New and cumulative COVID-19 cases by notification date



(1) change versus previous month

Hong Kong Clinical Trial Insights

| | |
|-------------------------------|---|
| Feasibility | <ul style="list-style-type: none"> Majority of sites continue to be very interested in new studies. |
| Ethics and Governance | <ul style="list-style-type: none"> Review and approval of non-COVID-19 clinical trials are continuing as scheduled. |
| Recruitment | <ul style="list-style-type: none"> All top 10 sites are open for recruitment. |
| Participant visits | <ul style="list-style-type: none"> In public sites, subject visits are proceeding with no changes required. There has been limited impact for subjects that reside in China and seen in a few private sites and institutions. |
| Monitoring | <ul style="list-style-type: none"> Some public sites restrict onsite monitoring visits. Private sites remain opened. Negative PCR result or full Covid vaccination is required for on-site visit at some public sites. Pregnant visitors are restricted at some public sites. |
| IP Supply and delivery | <ul style="list-style-type: none"> No impact and the IP supply chain is operating with no restrictions. |
| General | <ul style="list-style-type: none"> Sites, Industry, Health Authority and ECs coordinating activities to ensure subject safety and trial continuity. 100% of Novotech staff can work remotely with office access if required. State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation. DoH approved Pfizer and Sinovac vaccines. |
| COVID-19 Trials | <ul style="list-style-type: none"> High levels of investigator interest, institutional support, and acceleration of processes from ethics/regulatory authorities for COVID-19 trials. |

Top biotech sites: High level status

| | Ethics/ Gov | Site Initiation | Recruitment | Participant visits | Monitoring | COVID-19 trials |
|---|-------------|--------------------|-------------|--------------------|-------------------------|-----------------|
| Queen Mary Hospital | Available | Available | Available | Available | Available onsite | Expedited |
| Prince of Wales Hospital | Available | Available/Remote | Available | Available | Available onsite/remote | Expedited |
| Princess Margaret Hospital | Available | Available (remote) | Available | Available | Remote | Expedited |
| Queen Elizabeth Hospital | Available | Available | Available | Available | Available onsite | Expedited |
| Alice Ho Miu Ling Nethersole Hospital | Available | Available | Available | Available | Available onsite | Expedited |
| Tuen Mun Hospital | Available | Available (remote) | Available | Available | Remote | Expedited |
| Humanity & Health Clinical Trials Center | Available | Available | Available | Available | Available onsite | - |
| Pamela Youde Nethersole Eastern Hospital | Available | Available | Available | Available | Available onsite | Expedited |
| Hong Kong United Oncology Centre | Available | Available | Available | Available | Available onsite | - |
| UNIMED Medical Institute | Available | Available | Available | Available | Available onsite | - |

Novotech monitors activity for all sites. Please contact your project manager for an update